REFERENCES
- Fotherby K, Caldwell A. New progestogens in oral contraception. Contraception 1994; 49: 1–32
- Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995; 50: 364–95
- Oosterbaan HP. An open-label study of the effects of a 24-day regimen of gestodene 60 (ig/ethinylestradiol 15 (ig on endometrial histologic findings in healthy women. Eur J Contracept Reprod Health Care 1999; 4 (Suppl 2): 3–8
- Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial nfarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129–40
- Schwartz SM. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997; 127: 596–603
- Lidegaard L, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies; Contraception 1996; 53: 135–9
- Fauser BCJM, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997; 18: 71–106
- Gestodene Study Group 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 |^g and ethinylestradiol 15 |ig. Eur J Coittracept Reproci Health Care 1999; 4 (Suppl 2): 9–15
- Sullivan H, Furniss H, Spona J, Elstein M. Effects of 21-day and 24-day oral contraceptive regimens containing gestodene (60 \Xg) and ethinyl estradiol (15 |ig) on ovarian activity. Fértil Steril 1999; 72: 115–20